Quarterly report pursuant to Section 13 or 15(d)

Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative)

v3.8.0.1
Nature of Operations and Summary of Significant Accounting and Reporting Policies (Details Narrative) - USD ($)
 3 Months Ended 6 Months Ended
Apr. 20, 2017
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Jun. 30, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock, shares authorized 100,000,000 400,000,000   400,000,000   400,000,000
Common stock, par value $ 0.001 $ 0.001   $ 0.001   $ 0.001
Preferred stock, shares authorized 1,500,005 1,500,005   1,500,005    
Reverse stock split one-for-two hundred and fifty (1:250)          
Cash equivalents      
Value added tax receivable   4,386   4,386   $ 8,111
Research and development expense   1,034,729 $ 167,202 1,598,468 $ 328,399  
Research and development tax credit   $ 180,278 $ 180,278  
Employee Stock Option [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Antidilutive securities excluded from computation of earnings per share, amount       572,000    
Warrant [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Antidilutive securities excluded from computation of earnings per share, amount       149,517    
Common Stock [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Antidilutive securities excluded from computation of earnings per share, amount       47,599,059    
Minimum [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock, shares authorized   100,000,000   100,000,000    
Maximum [Member]            
Accumulated Other Comprehensive Income (Loss) [Line Items]            
Common stock, shares authorized   400,000,000   400,000,000